

## Index

Note: page numbers in *italics* refer to figures, those in **bold** refer to tables.

activated partial prothrombin time (APPT) 62 activated protein C 64 acute lymphoblastic leukaemia (ALL) 33, 34, 34 children 33, 34, 38 clinical features 34-35, diagnosis 35-37 epidemiology 34 treatment 38-39 acute myeloid leukaemia (AML) 33, 34, 34 clinical features 34-35 diagnosis 35-37, 36 epidemiology 34 hyperviscosity 85, 85 relapse management 38 treatment 37-38 acute promyelocytic leukaemia (APL) 35 acute T-cell leukaemia/lymphoma (ATLL) 68 ADAMTS13 deficiency 45, 90 alemtuzumab 91 Alport syndrome 43 amyloid deposition in multiple myeloma 58 anaemia 4 acute leukaemia 34 chronic disease 82 hereditary 13-18 hypochromic 3 older adults 81-82, 82 see also specific types anagrelide 23, 25 anencephaly 9 angiogenesis inhibitors 72 antibiotics 91 anticoagulation 88-89 antiphospholipid antibodies 64 antiphospholipid syndrome 45  $\alpha_2$ -antiplasmin 62 antithrombin 64

anti-X inhibitors 88-89

apixaban 65

aplastic anaemia, macrocytosis 10 apoptosis modulators 96 aspirin platelet dysfunction 45, 89 polycythaemia vera 22 thrombocythaemia 25 Auer rods 34 autoantibodies, macrocytic anaemia 10 autoimmune disease 68 azacitidine 39, 54 azathioprine 10, 47 B-cell signalling 72, 72 inhibitors 72 BCR-ABL mutations 29, 29, 31, 96 Bcr-Abl transcript numbers 30 Bernard-Soulier syndrome 43, 43 Blackfan-Diamond anaemia 19 bleeding 88-90 acute leukaemias 35 anticoagulation 88-89 causes 88 hyperviscosity syndrome 85 infants/neonates 46 platelet disorders 45, 46-47, 89-90 uraemic patients 45 bleeding disorders 61-63 acquired 63 congenital 62-63 history 61-62 investigations 62 see also coagulation abnormalities; coagulopathy bleeding time, platelet disorders 46, 62 blinatumumab 96 blood count 3 blood transfusion

myelodysplastic syndromes 52, 54 myelofibrosis 26 post-transfusion purpura 44 sickle cell crises 15, 87 thalassaemias 18 thrombocytopenia 45 blood viscosity 85, 85, 86, bone marrow acute leukaemias 35 aspiration 35 biopsy 24, 35, 68 CML 27, 29 cytogenetic analysis 24 examination 11, 11 failure/suppression 33, 34, 43, 83 fibrosis 25-26 lymphoproliferative disorders 68, 70 megaloblastic 7, 8, 11 multiple myeloma 55, 58 myelodysplastic syndromes 11, 50 stem cell collection 75 bone marrow transplantation 26, 47 bortezomib 59 bosutinib 31 Bruton tyrosine kinase (BTK) 96 Burkitt lymphoma 67, 73 calreticulin 21 cardiovascular disease 10, 22, 23, 25, 31 folate deficiency 10 central nervous system (CNS) acute leukaemias 37 lymphoproliferative disorders 71 chelating agents, thalassaemia 18

chemotherapy

CML 32

hyperviscosity 86

acute leukaemia 37-39, 86

chronic lymphocytic leukaemia 73







disseminated intravascular coagulation 47, 90

iron deficiency anaemia 5



spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor IX gene therapy 93–94, 94 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93–94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	chemotherapy (cont'd)	dabigatran 65, 88	ferrous salts 4
mydodysplastic syndromes 30,54	lymphoproliferative disorders 71	danazol 26	fetal haemoglobin (Hb F) 13
mydodysplastic syndromes 30,54	multiple myeloma 59	decitabine 54	fibrinogen 41, 62, 89–90
side-effects 37 stern cell transplantation and 75,76 children All 3, 33, 43,38 iron deficiency 3 1		deep vein thrombosis (DVT) 63, 63	
stern cell transplantation and 75,76 children deficiency ALI, 33, 34, 38 desferriorantine 18 description infants, neonates diffuse large P-cell Jymphoma (DLBCL) 73 stern cell transplantation 76 see also infants, neonates diffuse large P-cell Jymphoma (DLBCL) 73 stern cell transplantation 76 desmogressin 47, 63, 89 deficiency 8, 9, 11, 82 diffuse large P-cell Jymphoma (DLBCL) 73 prognacy 8, 9 deficiency 8, 9, 11, 82 diffuse large P-cell Jymphoma (DLBCL) 73 prophysias 12 treatment 12 description inhibitors 88–89 difuse thromosome, 5q deletion 50 (71, 73 infections 91, 91 older adults 83 staging, 69, 70 chronic mypeloid leukaemia (CML) 27–31 blast crisis 27, 31–32, 31 diagnosis 29 phases 27, 27, 28 treatment 27, 89–90 phases 27, 27, 28 phases 27, 27, 28 phases 27, 27, 28 phases 27, 27, 28 phase 28, 27, 28 phase 27, 27, 28 phase 28, 27, 28 phase 27, 27, 28 phase 28, 27, 28 phase 27		-	• •
children ALI. 13, 34, 38 iron deficiency 3 see also infants, reconstes diffuse large B-cell lymphoma (DLBCL) 73 see also infants, reconstes diffuse large B-cell lymphoma (DLBCL) 73 pregnancy 8, 9 prophylatus 12 deficiency 8, 9, 11, 82 deficiency 8, 9 prophylation 12 deficiency 8, 9, 11, 82 deficiency 8, 9 folical fractures 89 folical returns 89 foli	stem cell transplantation and 75, 76		fludarabine 91
ALL 33.43.28 desferionamine 18 assay 10 stem cell transplantation 76 see also infants recontes chimeric entiger neceptor T cells 96 thromosome, 50 deletion 50 cluments or method the content of the cont		deferiprone 18	fluorescent in situ hybridization (FISH) 69
disastin dit transplantation 76 see also infants; neonates diffuse large B-cell lymphoma (DLBCL) 73 pregnancy 8, 9 11, 12 2 pregnancy 8, 9 1, 12 2 pregnancy 9, 12 2 distert intake 8 1 distert thrombic mishibitors 8-8 9 clinical features 89 clinical features 89 thrombo-cytopenia 45, 89-90 thrombicytopenia 45, 89-90 phases 27, 27, 28 1 phases 27, 27, 28 1 phase 27, 27, 28 1		_	·
stem cell transplantation 76 see also infants, neantes chimeric antigen receptor T cells 96 chromosome, 5q deletion 50 chronic lymphocytic leukaemia (CLL) 68, 68, 71, 73 infections 91, 97 older adults 83 cause 89 chronic myeloid leukaemia (CML) 27-31 blast crisis 27, 31-34, 31 diagnosis 29 pathophysiology 28-29 pathophysiology 28-29 pathophysiology 28-29 pathophysiology 28-29 pathophysiology 28-29 pathophysiology 28-30 chronic myeloimonocytic leukaemia (CMML) 50, 51 celf palate 9 clorabilities 69 clorabilities			
see also infants; neonates chimeric antigen neceptor T cells 96 chromosome, 5q deletion 50 chromosome,			•
chimeric antigen receptor Teclls 96 chromosome, 5q deletion 50 cautie leukaemia (CLL) 50, 51 chromosome, 5q deletion 50 cautie leukaemia 55 cause 80 chromosome, 5q deletion 50 caute leukaemia 55 cause 80 chromosome, 5q deletion 50 caute leukaemia 55 cause 80 chromosome, 5q deletion 50 caute leukaemia 55 cause 80 chromosome, 5q deletion 50 cause 80 chromosome, 5q deletion 50 cause leukaemia 55 cause 80 chromosome, 5q deletion 50 cause leukaemia 55 cause 80 chromosome, 5q deletion 50 cause leukaemia 55 cause 80 chromosome, 5q deletion 50 cause leukaemia 55 cause 80 chromosome, 5q deletion 50 cause 80 chromosome, 5q deletion 50 cause leukaemia 55 cause 80 chromosome, 5q deletion 50 cause 80 chromosome, 5p deletion 50 phylophypologome, 5p, 7p, 30 congulation factor 50, 30 chronic myelomomocytic leukaemia (CMM). 50 DNA methylation 96 Celetry people 81-84 cell deletry 90 congulation abnormalities 90 congulation cascale 62, 62 care also bleeding disorders; coagulation abnormal		•	·
chromonen, Sq deletion 50 chromic lymphocytic leukaemia (CIL) 68, 68, 71, 73 infections 91, 91 older adults 83 staging 69, 70 chromic myeloid leukaemia (CML) 27–31 blast crisis 27, 31–32, 37 diagnosis 29 pathophysiology 28–29 pathophysiology			
chronic lymphocytic leukaemia (CLL) 68, 68, 71, 73 infections 91, 91 older adults 83 causes 89 chronic myeloid leukaemia (CML) 27–31 blast crisis 27, 31–32, 31 diagnosis 29 pathophysiology 28–20 pat			
infections 91,91 acute leukaemia 55 causes 89 clinical features 89 clini	_		
infections 91, 91 older adults 83 staging 69, 70 chronic myeloid leukaemia (CML) 27–31 blast crisis 27, 31–32, 31 diagnosis 29 phases 27, 27, 28 phases 27, 27, 28 DNA methyltation 96 phases 27, 27, 28 DNA methyltansferase inhibitors 96 phases 27, 27, 28 DNA methyltansferase inhibitors 96 phases 28 clorid myelomonocytic leukaemia (CMML) 50, 51 cleft palate 9 clorality studies 69 coagulation abnormalities 35, 62, 63 inherited 61 see also bleeding disorders, coagulopathy coagulation factors 64, 93 recombinant 63 see also hamed factors coagulation factors 64, 93 recombinant 63 see also hamed factors coagulation factors 64, 93 recombinant 63 see also hamed factors coagulation factors 64, 93 recombinant 63 see also hamed factors coagulation factors 64, 93 recombinant 63 see also hamed factors coagulation factors 64, 93 recombinant 63 see also hamed factors coagulation factors 64, 93 recombinant 63 see also bleeding disorders, coagulopathy myelodysplastic syndromes 49 endoscopy 11 coagulation factors 64, 93 recombinant 63 see also bleeding disorders, coagulation abnormalities cobalamin see vitamin B coelias classes (gluten-induced enteropathy) 8, 11 autoantibodies 10, 11 computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 164 refactor V 16			•
older adults 83 staging 69,70 chronic myelodi leukaemia (CML) 27-31 blast crisis 27, 31-32, 31 diagnosis 29 pathophysiology 28-29 pa			
staging 69, 70 chronic myeloid leukaemia (CML) 27-31 blast crisis 27, 31-32, 31 thrombocytopenia 45, 89-90 plast crisis 27, 31-32, 31 thrombocytopenia 45, 89-90 plast crisis 27, 31-32, 31 treatment 47, 89-90 plast crisis 27, 27, 28 DNA methylation 96 treatment 29-31 tyrosine kinase inhibitors 30, 30 thronic myelomonocytic leukaemia (CMML) 50, 51 cleft palate 9 cleft plate 9 clopalute 69 clopalute 69 congulation abnormalities 35, 62, 63 arise also bleeding disorders; coagulopathy coagulation cascade 62, 64 coagulopathy 61-63 see also bleeding disorders; coagulopathy coagulation factors 64, 93 recombinant 63 see also bleeding disorders; coagulation abnormalities 62 coagulopathy 61-63 acquirted 63 differential diagnosis 62 see also bleeding disorders; coagulation abnormalities cobalamin see vitamin B coeliac disease (gluten-induced enteropathy) disorders 70, 70 myelodysplastic syndromes 52 genetic expression modulation 96 erythrobasts, megaloblastic 8 erythrobasts, megaloblastic 8 erythropasts, megaloblastic 8 ery			
chronic myeloid leukaemia (CML) 27-31			
blast crisis 27, 31-32, 31 diagnosis 29 treatment 47, 89-90 phases 27, 27, 28 DNA methylation 96 tyrosine kinase inhibitors 30, 30 thronic myelomonocytic leukaemia (CMML) 50, 51 50, 51 cleft palate 9 clonality studies 69 clonality studies 69 clonality studies 69 clonality studies 35, 62, 63 acute leukaemias 35 inherited 61 see abso bleeding disorders; coagulopathy cagulation cascade 62, 62 cagulation factors 64, 93 recombinant 63 see abso manuel factors coagulation screening tests 62 coagulation screenin			11con 11ozen piaonia (111) 17, 50, 51
diagnosis 29 treatment 47, 89-90 gastritis, atrophic 8, 11 pathophysiology 28-29 DNA chips 94 gene expression profiling 69, 94 gene from the property of the path	•	•	gastrectomy 11
pathophysiology 28-29 phases 27, 27, 28 DNA methylation 96 treatment 29-31 tyrosine kinase inhibitors 30, 30 dysplastic features 50, 51 trontiem yelomonocytic leukaemia (CMML) 50, 51 cleft palate 9 clopidogrel 45, 89 clopidogrel 45, 89 coagulation abnormalities 35, 62, 63 inherited 61 see also mamed factors coagulation factors 64, 93 recombinant 63 see also named factors coagulation factors 64, 93 recombinant 63 see also named factors coagulation scande factors coagulation scandification shormalities coagulation factors 64, 93 acquired 63 differential diagnosis 62 see also bleeding disorders; coagulation abnormalities coagulation factors coagulation abnormalities coagulation factors coagulation factors coagulation abnormalities coagulation factors coagulat			
phases 27, 27, 28 treatment 29-31 tyrosine kinase inhibitors 30, 30 chronic myelomonocytic leukaemia (CMML) 50, 51 cleft palate 9 clonality studies 69 clonality studies 69 coagulation abnormalities 35, 62, 63	-		
treatment 29-31 tyrosine kinase inhibitors 30, 30 dysplastic features 50, 51 see also myelodysplastic syndromes (MDS) 50, 51 cleft palate 9 clopidogrel 45, 89 clopidogrel 45, 89 coagulation abnormalities 35, 62, 63 anaemia 81-82, 82 colapidation abnormalities 82 inherited 61 anaemological malignancies 82-84, 83 glycoprotein III-IX complex 41 glycoprotein III-IX complex 42 glycoprotein III-IX complex 42 glycoprotein III-IX complex 43 glycoprotein III-IX complex 42 glycoprotein III-IX complex 43 glycoprotein III-IX complex 43 glycoprotein III-IX complex 43 glycoprotein III-IX complex 44 glycoprotein III-IX complex 44 glycoprotein III-IX complex 44 glycoprotein III-IX complex 44 glycoprotein III-IX		•	
chronic myelomonocytic leukaemia (CMML)  50, 51  cleft palate 9  clonality studies 69  clonality studies 69  clonality studies 69  clonality studies 69  clopidogred 45, 89  coagulation abnormalities 35, 62, 63  actute leukaemias 35  inherited 61  haematological malignancies 82–84, 83  inherited 61  haematological malignancies 82–84, 83  givcoprotein Ib-IX complex 41  givcoprotein Ib-IIII antaquonists 45  see also Dieceding disorders; coagulopathy  coagulation cascade 62, 62  coagulation factors 64, 93  recombinant 63  see also mand factors  coagulation screening tests 62  coagulation screening tests 62  coagulation screening tests 62  coagulation screening tests 62  coagulation abnormalities  coadulation factors (as a paper 123  differential diagnosis 62  see also Bleeding disorders; coagulation  abnormalities  cobalamin see vitamin B  coeliac disease (gluten-induced enteropathy)  disorders 70, 70  factor V Leiden 64  graft-versus-host disease (G-CSF) 54  green therapy 94  haemoglobin 13  haemoglobin 13  haemoglobin pathies 13-18  gene therapy 94  haemolytic inaemia 12, 18  haemoglotic thrombocytopenic purpura 41  haemolytic disease of the newborn 44  haemolytic uraemis syndrome 45  haemophilia 62-63, 93-94  haemophilia 62-63, 93  prome editing 95-96  genomics 94-95  Glanzmann thrombasthenia 43, 47, 89  gloositis 9, 9  glucose-6-phosphatase deficiency (GePD) 1  glycoprotein Ib-IX complex 41  graft-versus-host disease (GVHD) 76, 77  granuloses-64, 93  acute 77-78, 77, 78  donor T cells 77  paraturersus-host disease (GVHD) 76, 77  granulosers coagulation 96  crythropoietin  myelodysplastic syndromes 52  granulosers 60-00ny-stimulating factor  (G-CSF) 54  green therapy 94  haemolytic disease of the newborn 44  haemolytic uraemic syndrome 45  haemophilia 62-63, 93  eytomegalovirus		•	
chronic myelomonocytic leukaemia (CMML)  50, 51  61 ceft plate 9  61 cleft plate 9  61 cleft plate 9  61 clonality studies 69  62 clonality studies 69  63 coagulation abnormalities 35, 62, 63  64 coagulation abnormalities 35, 62, 63  65 coagulation abnormalities 35, 62, 63  66 coagulation abnormalities 35, 62, 63  67 coagulation accade 62, 62  68 coagulation factors 64, 93  69 coagulation accade 62, 62  60 coagulation accade 62, 62  60 coagulation accade 62, 62  60 coagulation factors 64, 93  60 coagulation accade 62, 62  60 coagulation accade 62, 62  60 coagulation accade 62, 62  60 coagulation factors 64, 93  60 coagulation factors 64, 93  60 coagulation screening tests 62  60 coagulopathy  60 coagulation screening tests 62  60 coagulation			-
cleft palate 9 elderly people 81–84 genome editing 95–96 genomics 94–95 clonality studies 69 anaemia 81–82, 82 chronic disease 82 glossitis 9, 9 coagulation abnormalities 35, 62, 63 iron deficiency 82 acute leukaemias 35 megaloblastic 82 glycoprotein Ib-IIX complex 41 glycoprotein ib-IX complex 41 glycoprotein in Ib/III antagonists 45 see also bleeding disorders; coagulopathy myelodysplastic syndromes 49 graft-versus-leukaemia 62, 62 erythroblasts, megaloblastic 8 erosulopathy coagulation cascade 62, 62 erythroblasts, megaloblastic 8 erosulopathy encephalocoele 9 graft-versus-leukaemia 63 endoscopy 11 donor T cells 77 acute 77–78, 77, 78 donor T cells 77 chronic 77, 78–79, 78 graft-versus-leukaemia 64 coagulation acute for coagulation acu	•	, 1	•
cleft palate 9 elderly people 81–84 genomics 94–95 (Glanzmann thrombasthenia 43, 47, 89 clonality studies 69 choralty studies 69 coagulation abnormalities 35, 62, 63 iron deficiency 82 glucose-6-phosphatase deficiency (G6PD) 1 acute leukaemias 35 megalobiastic 82 glycoprotein Ib-IX complex 41 glycoprotein 41 graft-versus-host disease (GVHD) 76, 77 caegulation cascade 62, 62 end-organ damage, multiple myeloma 58 acute 77–78, 77, 78 donor T cells 77 endoscopy 11 donor T cells 77 endoscopy 11 donor T cells 77 endoscopy 11 donor T cells 77 expression modulation 96 cagulation screening tests 62 erythrocytosis 22, 22 77, 79–3 acquired 63 apparent 23 graft-versus-leukaemia (GVL) effect 76, 20 acquired 63 apparent 23 graft-versus-leukaemia (GVL) effect 76, 20 acquired 63 differential diagnosis 62 causes 22 granulocyte colony-stimulating factor differential diagnosis 62 acute 20 graphodysplastic syndromes 52 genetic control 14 developmental changes 13 haemoglobin 13 essential thrombocythaemia 22 genetic control 14 developmental changes 13 normal ranges 81 haemoglobinopathies 13–18 gene therapy 94 haemolytic anaemia 12, 18 autoantibodies 10, 11 24–25, 24 haemolytic anaemia 12, 18 autoimmune 68 gene therapy 94 haemolytic disease of the newborn 44 haemolytic uraemic syndrome 45 haemophilia 8 d-2-63, 63 gene therapy 93 haemophilia 8 d-2-63, 93 -94 haemophilia 6 d-2-63, 93 -94 haemophilia 6 d-2-63, 93 -94 haemophilia 6 d-2-63, 93 haemophilia 6 d	•	see also myelodyspiastic syndromes (MDS)	•
clonality studies 69 annemia 81–82, 82 Glanzmann thrombasthenia 43, 47, 89 clopidogrel 45, 89 chronic disease 82 glossitis 9, 9 coagulation abnormalities 35, 62, 63 iron deficiency 82 glucose-6-phosphatase deficiency (G6PD) 1 acute leukaemias 35 megaloblastic 82 glycoprotein Ib-IIX complex 41 glycoprotein Ib-III antagonists 45 see also bleeding disorders; coagulopathy myelodysplastic syndromes 49 glycoprotein Ib-III antagonists 45 see also bleeding disorders; coagulopathy coagulation cascade 62, 62 encephalocoele 9 graft-versus-host disease (GVHD) 76, 77 arecombinant 63 endoscopy 11 donor T cells 77 see also manuel factors epigenetic expression modulation 96 coagulation screening tests 62 erythroblasts, megaloblastic 8 graft-versus-leukaemia (GVL) effect 76, coagulopathy 61–63 apparent 23 graft-versus-leukaemia (GVL) effect 76, coagulopathy 61–63 apparent 23 granulocyte colony-stimulating factor differential diagnosis 62 causes 22 granulocyte colony-stimulating factor differential diagnosis 62 ese also bleeding disorders; coagulation abnormalities erythropotetin subnormalities erythropotetin see vitamin B myelodysplastic syndromes 52 geselated for the proposed factor V 64 haemoglobin 13 genetic control 14 developmental changes 13 normal ranges 81 autoantibodies 10, 11 24–25, 24 developmental changes 13 normal ranges 81 autoantibodies 10, 11 24–25, 24 haemoglytic anaemia 12, 18 agene therapy 94 haemoglytic disease of the newborn 44 haemoglytic disease 78 factor VIII, recombinant 47 spinal cord compression 88 factor VIII, ecombinant 47 haemoglytic disease of the newborn 44 haemoplytic disease of the newborn 45 haemoplytic disease of the new		11 1 1 01 04	
clopidogrel 45, 89 chronic disease 82 glossitis 9, 9 coagulation abnormalities 35, 62, 63 iron deficiency 82 glucose-6-phosphatase deficiency (G6PD) 1 acute leukaemias 35 megaloblastic 82 inherited 61 haematological malignancies 82-84, 83 glycoprotein IIb/IIIa antagonists 45 see also bleeding disorders; coagulopathy myelodysplastic syndromes 49 glycoprotein IIb/III antagonists 45 coagulation cascade 62, 62 encephalococle 9 graft-versus-host disease (GVHD) 76, 77 coagulation factors 64, 93 end-organ damage, multiple myeloma 58 recombinant 63 endoscopy 11 donor T cells 77 see also named factors coagulation screening tests 62 erythroblasts, megaloblastic 8 graft-versus-leukaemia (GVL) effect 76, coagulopathy 61-63 erythrocytosis 22, 22 77, 79- acquired 63 graft-versus-leukaemia (GVL) effect 76, coagulopathy 61-63 erythropicitin cobalamin see vitamin B myelodysplastic syndromes 52 see also bleeding disorders; coagulation abnormalities erythropoietin cobalamin see vitamin B myelodysplastic syndromes 52 coeliad disease (gluten-induced enteropathy) g, 1,1 autoantibodies 10, 11 24-25, 24 haemoglobin 13 computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 corticosteroids 47 factor V Leiden 64 graft-versus-host disease 78 factor VIIa, recombinant 47 thrombotic thrombocytopenic purpura 49 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 spinal cord compression 89 factor IX multiple myeloma 55 deficiency 62 myelodysplastic syndromes 50 gene therapy 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemophilia 62-63, 93-94, 94 haemophilia 62-63, 93-94, 94 haemophilia 62-63, 93-94	-		e e e e e e e e e e e e e e e e e e e
coagulation abnormalities 35, 62, 63 iron deficiency 82 megaloblastic 82 glycoprotein Ib-IX complex 41 inherited 61 haematological malignancies 82–84, 83 glycoprotein Ib-IX complex 41 inherited 61 see also bleeding disorders; coagulopathy myelodysplastic syndromes 49 glycoprotein IIb/IIIa antagonists 45 see also bleeding disorders; coagulopathy encephalocoele 9 coagulation cascade 62, 62 encephalocoele 9 coagulation factors 64, 93 end-organ damage, multiple myeloma 58 recombinant 63 endoscopy 11 donor T cells 77 see also named factors erythroblasts, megaloblastic 8 crythrocytosis 22, 22 graft-versus-host disease (GVHD) 76, 77 acquired 63 erythrocytosis 22, 22 granulocyte colony-stimulating factor differential diagnosis 62 erythrocytosis 22, 22 granulocyte colony-stimulating factor differential diagnosis 62 see also bleeding disorders; coagulation sevolution abnormalities erythropietin haemoglobin 13 haemoglobin 13 haemoglobin 13 haemoglobin 13 haemoglobin 14 developmental changes 13 normal ranges 81 haemoglobin 14 developmental changes 13 normal ranges 81 haemoglobin opathies 10,11 24–25, 24 haemoglobinopathies 13–18 gene therapy 94 haemoglobin opathies 13–18 gene therapy 94 haemoglobin 68 graft-versus-host disease 78 factor VIIa, recombinant 47 thrombotic thrombocytopenic purpura 45 acute leukaemias 36, 36 gene therapy 94 haemoplitic anaemia 12, 18 cuttle leukaemias 36, 36 lymphoproliferative disorders 69 factor VII 62, 64 gene therapy 94 haemoplitic anaemia 15, 36 lymphoproliferative disorders 69 factor VII 62, 64 gene therapy 94 haemoplitia 62–63, 63, 30 lymphoproliferative disorders 69 gene therapy 94 haemophilia 8 62–63, 93 epithemeoplator (CMV) 77 factor XIII deficiency 62 haemopliia 8 62–63, 93 haemophilia 8 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemoplatias 46–63, 93 haemoplatias 46–64, 91	•		
acute leukaemias 35 megaloblastic 82 glycoprotein Ib-IX complex 41 inherited 61 haematological malignancies 82–84, 83 glycoprotein Ib/IIIa antagonists 45 see also bleeding disorders; coagulopathy myelodysplastic syndromes 49 glycoproteins 41 graft-versus-host disease (GVHD) 76,77 coagulation cascade 62, 62 encephaloccode 9 graft-versus-host disease (GVHD) 76,77 recombinant 63 endoscopy 11 donor T cells 77 see also named factors endoscopy 11 donor T cells 77 see also named factors erythroblasts, megaloblastic 8 graft-versus-leukaemia (GVL) effect 76, coagulopathy 61–63 erythrocytosis 22, 22 77,79– acquired 63 apparent 23 granulocyte colony-stimulating factor differential diagnosis 62 causes 22 (G-CSF) 54 grey bleeding disorders; coagulation abnormalities erythropoietin myelodysplastic syndromes 52 genetic control 14 coeliac disease (gluten-induced enteropathy) polycythaemia 22 genetic disease (gluten-induced enteropathy) polycythaemia 22 developmental changes 13 normal ranges 81 haemoglobinopathies 13–18 gene therapy 94 haemoglobinopathies 13–18 gene therapy 94 haemolytic anaemia 12, 18 corticosteroids 47 factor V Leiden 64 autoimmune 68 graft-versus-host disease 78 factor V III 62, 64 haemolytic disease of the newborn 44 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 spinal cord compression 86 factor V IX gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor V IX gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor V IX gene therapy 94 haemophilia 62–63, 93 haemophilia 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61			
inherited 61  see also bleeding disorders; coagulopathy coagulation cascade 62, 62  encephalocoele 9  encephalocoele 9  recombinant 63  see also named factors coagulation sereening tests 62  coagulation sereening tests 62  coagulation factors differential diagnosis 62  see also bleeding disorders; coagulation abnormalities  cobleding disorders; coagulation abnormalities  cobladamin see vitamin B  coeliac disease (gluten-induced enteropathy)  8, 11  autoantibodies 10, 11  computed tomography (CT), lymphoproliferative disorders 70, 70  corticosteroids 47  graft-versus-host disease 78  factor V IIa, recombinant 47  factor V IIa, recombinant 47  spen therapy 94  deficiency 62, 94  multiple myeloma 58  glycoprotein IIb/IIIa antagonists 45  glycoproteins 41  graft-versus-host disease (GVHD) 76, 77  glycoprotein IIb/IIIa antagonists 45  glycoproteins 41  graft-versus-host disease (GVHD) 76, 77  acute 77-8, 77, 78  acute 77-8, 77, 79  granulocyte colony-stimulating factor  (G-CSF) 54  grep platelet syndrome 43  haemoglobin 13  genetic control 14  developmental changes 13  normal ranges 81  haemoglobin 13  genet therapy 94  haemolytic anaemia 12, 18  autoinmune 68  thrombotic thrombocytopenic purpura 4:  haemolytic disease of the newborn 44  deficiency 62, 94  haemolytic uraemic syndrome 45  haemolytic uraemic syndrome 45  haemolytic uraemic syndrome 45  haemolytic uraemic syndrome 45  haemolytic anaemia 12, 93  gene therapy 93-94, 94  haemophilia 62-63, 63  gene therapy 93-94, 94  haemophilia 62-63, 93  haemostais 41-42, 61		•	
see also bleeding disorders; coagulopathymyelodysplastic syndromes 49glycoproteins 41coagulation cascade 62, 62encephalocoele 9graft-versus-host disease (GVHD) 76, 77coagulation factors 64, 93end-organ damage, multiple myeloma 58acute 77-78, 77, 78recombinant 63endoscopy 11donor T cells 77see also named factorsepigenetic expression modulation 96chronic 77, 78-79, 78coagulation screening tests 62erythrolasts, megaloblastic 8graft-versus-leukaemia (GVL) effect 76,coagulopathy 61-63erythrocytosis 22, 2277, 79-acquired 63apparent 23granulocyte colony-stimulating factordifferential diagnosis 62causes 22(G-CSF) 54see also bleeding disorders; coagulationsecondary 23grey platelet syndrome 43abnormalitieserythropoietinhaemoglobin 13cobalamin see vitamin Bmyelodysplastic syndromes 52genetic control 14coeliac disease (gluten-induced enteropathy)polycythaemia 22genetic control 14developmental changes 13acute 13haemoglobinopathies 13-18computed tomography (CT), lymphoproliferativegenet therapy 94haemoglobinopathies 13-18disorders 70, 70factor V 64haemolytic anaemia 12, 18corticosteroids 47factor V Leiden 64autoimmune 68graff-versus-host disease 78factor VIIa, recombinant 47thrombotic thrombocytopenic purpura 45spinal cord compression 88factor VIII 62, 64haemolytic uraemic syndrome 45acute leukaemias 36, 36gene therapy 94 <t< td=""><td></td><td>-</td><td></td></t<>		-	
coagulation cascade 62, 62 encephalocoele 9 graft-versus-host disease (GVHD) 76, 77 coagulation factors 64, 93 end-organ damage, multiple myeloma 58 acute 77–78, 77, 78 recombinant 63 endoscopy 11 donor T cells 77 see also named factors epigenetic expression modulation 96 chronic 77, 78–79, 78 coagulation screening tests 62 erythroblasts, megaloblastic 8 graft-versus-leukaemia (GVL) effect 76, coagulopathy 61–63 erythrocytosis 22, 22 77, 79– granulocyte colony-stimulating factor differential diagnosis 62 causes 22 granulocyte colony-stimulating factor differential diagnosis 62 see also bleeding disorders; coagulation abnormalities erythropoietin haemoglobin 13 erythropoietin haemoglobin 13 erythropoietin haemoglobin 13 erythropoietin haemoglobin 13 seesated disease (gluten-induced enteropathy) golycythaemia 22 developmental changes 13 autoantibodies 10, 11 essential thrombocythaemia (ET) 21, normal ranges 81 haemoglobinopathies 13–18 gene therapy 94 disorders 70, 70 factor V 64 haemolytic anaemia 12, 18 autointious 47 factor V Leiden 64 autoimmune 68 graft-versus-host disease 78 factor VIII, recombinant 47 thrombocit thrombocytopenic purpura 45 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 ecytogenetics acute leukaemias 36, 36 gene therapy 94 haemolytic disease of the newborn 44 deficiency 62, 94 haemolytic disease of the newborn 45 haemophilia 62–63, 63, 63 lymphoproliferative disorders 69 factor IX gene therapy 93 haemophilia 62–63, 93 -94, 94 haemophilia 62–63, 93 -94, 94 haemophilia 62–63, 93 -94, 94 haemophilia 62–63, 93 -94 haemophilia 62–63, 93 -94 haemophilia 62–63, 93 -94 haemophilia 62–63, 93 eytomegalovirus (CMV) 77 factor XIII deficiency 62 haemophilia 62–63, 93 haemophilia 62–63, 9			
coagulation factors 64, 93 recombinant 63 replace also named factors replace also named factors replace also named factors replace and replace a			
recombinant 63 see also named factors coagulation screening tests 62 crythroblasts, megaloblastic 8 coagulation screening tests 62 coagulopathy 61–63 acquired 63 acquired 63 apparent 23 differential diagnosis 62 see also bleeding disorders; coagulation abnormalities cobalamin see vitamin B coeliac disease (gluten-induced enteropathy) 8, 11 autoantibodies 10, 11 computed tomography (CT), lymphoproliferative disorders 70, 70 factor V Leiden 64 graft-versus-host disease 78 spinal cord compression 88 factor VIII, ecombinant 47 spinal cord compression 88 factor VIII 62, 64 lymphoproliferative disorders 69 myelodysplastic syndromes 50 gene therapy 94 haemolytic uraemic syndrome 45 haemolytic uraemic syndrome 4			
see also named factors coagulation screening tests 62 coagulation screening tests 62 coagulation screening tests 62 coagulopathy 61–63 acquired 63 apparent 23 acquired 63 differential diagnosis 62 see also bleeding disorders; coagulation abnormalities cobalamin see vitamin B coeliac disease (gluten-induced enteropathy) 8, 11 autoantibodies 10, 11 computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 graft-versus-leukaemia (GVL) effect 76, acquired 63 apparent 23 granulocyte colony-stimulating factor (G-CSF) 54 grey platelet syndrome 43 haemoglobin 13 genetic control 14 coveliac disease (gluten-induced enteropathy) polycythaemia 22 developmental changes 13 autoantibodies 10, 11 computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 factor V Leiden 64 graft-versus-host disease 78 factor V VIIa, recombinant 47 factor V VIIa, recombinant 47 spinal cord compression 88 factor VIII 62, 64 deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 lymphoproliferative disorders 69 factor IX gene therapy 93 haemophilia 62–63, 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	-		
coagulation screening tests 62 erythroblasts, megaloblastic 8 graft-versus-leukaemia (GVL) effect 76, coagulopathy 61–63 erythrocytosis 22, 22 77, 79— acquired 63 apparent 23 granulocyte colony-stimulating factor differential diagnosis 62 causes 22 (G-CSF) 54 gree also bleeding disorders; coagulation abnormalities erythropoietin haemoglobin 13 genetic control 14 ocolaamin see vitamin B myelodysplastic syndromes 52 genetic control 14 oevelopmental changes 13 normal ranges 81 autoantibodies 10, 11 24–25, 24 haemoglobinopathies 13–18 gene therapy 94 deficiency 62, 94 haemolytic disease of the newborn 44 cytogenetics for IX gene therapy 94 haemophilia A 62–63, 93 ocytomegalovirus (CMV) 77 factor XIII deficiency 62 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62		17	
coagulopathy 61–63 erythrocytosis 22, 22 77, 79– acquired 63 apparent 23 granulocyte colony-stimulating factor differential diagnosis 62 causes 22 (G-CSF) 54 see also bleeding disorders; coagulation secondary 23 grey platelet syndrome 43 abnormalities erythropoietin haemoglobin 13 cobalamin see vitamin B myelodysplastic syndromes 52 genetic control 14 coeliac disease (gluten-induced enteropathy) polycythaemia 22 developmental changes 13 autoantibodies 10, 11 24–25, 24 haemoglobinopathies 13–18 computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 haemolytic anaemia 12, 18 corticosteroids 47 factor V Leiden 64 autoimmune 68 graft-versus-host disease 78 factor VIII 62, 64 haemolytic disease of the newborn 44 cytogenetics deficiency 62, 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor IX multiple myeloma 55 deficiency 62 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62	•		
acquired 63 apparent 23 granulocyte colony-stimulating factor differential diagnosis 62 causes 22 (G-CSF) 54  see also bleeding disorders; coagulation secondary 23 grey platelet syndrome 43 abnormalities erythropoietin haemoglobin 13  cobalamin see vitamin B myelodysplastic syndromes 52 genetic control 14  coeliac disease (gluten-induced enteropathy) polycythaemia 22 developmental changes 13 autoantibodies 10, 11 essential thrombocythaemia (ET) 21, normal ranges 81 autoantibodies 10, 11 24-25, 24 haemoglobinopathies 13-18  computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 haemolytic anaemia 12, 18  corticosteroids 47 factor V Leiden 64 graft-versus-host disease 78 factor VII a, recombinant 47 thrombotic thrombocytopenic purpura 49 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44  cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 gene therapy 94  multiple myeloma 55 deficiency 62 myelodysplastic syndromes 50 gene therapy 93  cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemophilia B 62-63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41-42, 61			
differential diagnosis 62 causes 22 (G-CSF) 54  see also bleeding disorders; coagulation abnormalities erythropoietin haemoglobin 13  cobalamin see vitamin B myelodysplastic syndromes 52 genetic control 14  coeliac disease (gluten-induced enteropathy) polycythaemia 22 developmental changes 13  s, 11 essential thrombocythaemia (ET) 21, normal ranges 81  autoantibodies 10, 11 24–25, 24 haemoglobinopathies 13–18  computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 haemoglobinopathies 12, 18  corticosteroids 47 factor V Leiden 64 autoimmune 68  graft-versus-host disease 78 factor VIIa, recombinant 47 thrombotic thrombocytopenic purpura 45  spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44  cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45  acute leukaemias 36, 36 gene therapy 94  haemophilia 62–63, 63  lymphoproliferative disorders 69 factor IX  gene therapy 93–94, 94  multiple myeloma 55 deficiency 62  myelodysplastic syndromes 50 gene therapy 93  cytomegalovirus (CMV) 77 factor XIII deficiency 62  haemophilia B 62–63, 93  cytomegalovirus (CMV) 77 factor XIII deficiency 62  haemostasis 41–42, 61		• •	
see also bleeding disorders; coagulation abnormalities erythropoietin baemoglobin 13 cobalamin see vitamin B coeliac disease (gluten-induced enteropathy) 8, 11 essential thrombocythaemia 22 genetic control 14 developmental changes 13 essential thrombocythaemia (ET) 21, normal ranges 81 autoantibodies 10, 11 computed tomography (CT), lymphoproliferative disorders 70, 70 factor V Leiden 64 graft-versus-host disease 78 spinal cord compression 88 factor VIII, recombinant 47 spinal cord compression 88 factor VIII 62, 64 cytogenetics acute leukaemias 36, 36 lymphoproliferative disorders 69 factor IX multiple myeloma 55 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	1		
abnormalities erythropoietin haemoglobin 13  cobalamin see vitamin B myelodysplastic syndromes 52 genetic control 14  coeliac disease (gluten-induced enteropathy) polycythaemia 22 developmental changes 13  8, 11 essential thrombocythaemia (ET) 21, normal ranges 81  autoantibodies 10, 11 24–25, 24 haemoglobinopathies 13–18  computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 haemolytic anaemia 12, 18  corticosteroids 47 factor V Leiden 64 autoimmune 68  graft-versus-host disease 78 factor VIII, recombinant 47 thrombotic thrombocytopenic purpura 49  spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45  acute leukaemias 36, 36 gene therapy 94 haemolytic uraemic syndrome 45  myelodysplastic syndromes 50 gene therapy 93 haemophilia 62–63, 93  cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61			
cobalamin see vitamin B myelodysplastic syndromes 52 genetic control 14  coeliac disease (gluten-induced enteropathy) polycythaemia 22 developmental changes 13  8, 11 essential thrombocythaemia (ET) 21, normal ranges 81  autoantibodies 10, 11 24–25, 24 haemoglobinopathies 13–18  computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 haemolytic anaemia 12, 18  corticosteroids 47 factor V Leiden 64 autoimmune 68  graft-versus-host disease 78 factor VIII, recombinant 47 thrombotic thrombocytopenic purpura 45  spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44  cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45  acute leukaemias 36, 36 gene therapy 94  multiple myeloma 55 deficiency 62  myelodysplastic syndromes 50 gene therapy 93  haemophilia A 62–63, 93–94  myelodysplastic syndromes 50  gene therapy 93  haemophilia B 62–63, 93  cytomegalovirus (CMV) 77 factor XIII deficiency 62  haemostasis 41–42, 61		•	
coeliac disease (gluten-induced enteropathy)  8, 11  autoantibodies 10, 11  computed tomography (CT), lymphoproliferative disorders 70, 70  factor V Leiden 64  graft-versus-host disease 78  spinal cord compression 88  factor V III 62, 64  cytogenetics  acute leukaemias 36, 36  lymphoproliferative disorders 69  myelodysplastic syndromes 50  gene therapy 94  haemoglobinopathies 13–18  gene therapy 94  haemolytic anaemia 12, 18  thrombotic thrombocytopenic purpura 45  haemolytic disease of the newborn 44  cytogenetics  deficiency 62, 94  multiple myeloma 55  deficiency 62  myelodysplastic syndromes 50  gene therapy 93  haemophilia 62–63, 93–94  haemophilia B 62–63, 93  cytomegalovirus (CMV) 77  factor XIII deficiency 62  haemostasis 41–42, 61			
8, 11 essential thrombocythaemia (ET) 21, normal ranges 81 autoantibodies 10, 11 24–25, 24 haemoglobinopathies 13–18 computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 haemolytic anaemia 12, 18 corticosteroids 47 factor V Leiden 64 autoimmune 68 graft-versus-host disease 78 factor VIII, recombinant 47 thrombotic thrombocytopenic purpura 45 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 gene therapy 94 haemolytic uraemic syndrome 45 lymphoproliferative disorders 69 factor IX gene therapy 93 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61			-
autoantibodies 10, 11  24–25, 24  haemoglobinopathies 13–18  gene therapy 94  disorders 70, 70  factor V 64  corticosteroids 47  graft-versus-host disease 78  spinal cord compression 88  factor VIII, recombinant 47  spinal cord compression 88  factor VIII 62, 64  cytogenetics  acute leukaemias 36, 36  lymphoproliferative disorders 69  myelodysplastic syndromes 50  gene therapy 93  factor XIII deficiency 62  myelodysplastic syndromes 50  factor XIII deficiency 62  factor XIII deficiency 62  haemostasis 41–42, 61			
computed tomography (CT), lymphoproliferative disorders 70, 70 factor V 64 haemolytic anaemia 12, 18 corticosteroids 47 factor V Leiden 64 graft-versus-host disease 78 factor VIII, recombinant 47 thrombotic thrombocytopenic purpura 49 spinal cord compression 88 factor VIII 62, 64 cytogenetics deficiency 62, 94 haemolytic disease of the newborn 44 cytogenetics acute leukaemias 36, 36 gene therapy 94 haemolytic uraemic syndrome 45 haemophilia 62–63, 63 gene therapy 94 haemophilia 62–63, 63 gene therapy 93 haemophilia A 62–63, 93-94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61		essential thrombocythaemia (ET) 21,	-
disorders 70, 70 factor V 64 haemolytic anaemia 12, 18 corticosteroids 47 factor V Leiden 64 autoimmune 68 graft-versus-host disease 78 factor VIIa, recombinant 47 thrombotic thrombocytopenic purpura 45 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor IX gene therapy 93-94, 94 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93-94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	•	24–25, 24	
corticosteroids 47 factor V Leiden 64 autoimmune 68 graft-versus-host disease 78 factor VIIa, recombinant 47 thrombotic thrombocytopenic purpura 49 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor IX gene therapy 93-94, 94 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93-94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61			0 17
graft-versus-host disease 78 factor VIIa, recombinant 47 thrombotic thrombocytopenic purpura 49 spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor IX gene therapy 93–94, 94 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93–94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	disorders 70, 70	factor V 64	haemolytic anaemia 12, 18
spinal cord compression 88 factor VIII 62, 64 haemolytic disease of the newborn 44 cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor IX gene therapy 93–94, 94 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93–94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61		factor V Leiden 64	autoimmune 68
cytogenetics deficiency 62, 94 haemolytic uraemic syndrome 45 acute leukaemias 36, 36 gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor IX gene therapy 93–94, 94 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93–94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	graft-versus-host disease 78	factor VIIa, recombinant 47	thrombotic thrombocytopenic purpura 45, 90
acute leukaemias 36, 36 gene therapy 94 haemophilia 62–63, 63 lymphoproliferative disorders 69 factor IX gene therapy 93–94, 94 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93–94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	spinal cord compression 88	factor VIII 62, 64	haemolytic disease of the newborn 44
lymphoproliferative disorders 69 factor IX gene therapy 93–94, 94 multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93–94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	cytogenetics	deficiency 62, 94	haemolytic uraemic syndrome 45
multiple myeloma 55 deficiency 62 haemophilia A 62–63, 93–94 myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	acute leukaemias 36, 36	gene therapy 94	haemophilia 62-63, 63
myelodysplastic syndromes 50 gene therapy 93 haemophilia B 62–63, 93 cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	lymphoproliferative disorders 69	factor IX	gene therapy 93–94, 94
cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	multiple myeloma 55	deficiency 62	haemophilia A 62-63, 93-94
cytomegalovirus (CMV) 77 factor XIII deficiency 62 haemostasis 41–42, 61	myelodysplastic syndromes 50	gene therapy 93	haemophilia B 62-63, 93
alloganaic stam call transplantation 77 Fanconi anagmia 10.42 Hashimoto's thursiditis 67	cytomegalovirus (CMV) 77	factor XIII deficiency 62	haemostasis 41-42, 61
anogenere stem ten transplantation // Fancoin anaemia 19,42 Trasminotos thyrotottis 0/	allogeneic stem cell transplantation 77	Fanconi anaemia 19, 42	Hashimoto's thyroiditis 67
CLL 91 ferritin, serum levels 3, 82 Hb Bart's hydrops fetalis 15, 17	CLL 91	ferritin, serum levels 3, 82	Hb Bart's hydrops fetalis 15, 17







HELLP syndrome 45	interferon $\alpha$ (IFN- $\alpha$ )	lymphadenopathy 68
neparin, venous thromboembolism treatment 65	CML treatment 29	lymphocytosis, incidental 68
neparin-induced thrombocytopenia 44-45, 47	polycythaemia vera 23	lymphoma
nepatosplenomegaly 68	thrombocythaemia 25	Burkitt 67, 73
nereditary anaemias 13–18	international normalised ratio (INR) 88	diffuse large B-cell (DLBCL) 73
nereditary spherocytosis 18	intravenous immunoglobulin 91	follicular (FL) 73
nerpes zoster 91	thrombocytopenia 47	mantle cell (MCL) 73
nistone deacetylases (HDACs) 96	iron 1	radiotherapy 71
Hodgkin's lymphoma (HL) 72–73	chelation 54	small lymphocytic 73
treatment 71, 72	daily requirements 2	staging 69, <b>70</b>
stem cell transplantation 76	intravenous preparations 4, 5	stem cell transplantation 76
nomocysteine serum assay 10	metabolism 1	T-cell 73
numan platelet antigen (HPA-1a) 44	replacement therapy 4, 4, 4	lymphoproliferative disorders (LPD) 67-73
nydrops fetalis 17	supplementation 4, 4, 4	classification 67, 72
nydroxycobalamin 11	failure to response 4–5	diagnosis 68-69
nydroxycarbamide (hydroxyurea) 15, 23, 25,	prophylactic 5	familial predisposition 67
26, 29	iron deficiency anaemia 1–3, 3	genetic causes 70
macrocytosis 10, 11	blood transfusion 5	heavy chain 69
nypercalcaemia 68	causes 2	imaging 70
hyperviscosity syndrome 85–86, 85, 86	diagnosis 1-2, 2, 3	low grade 69, 72, 73
symptoms and signs 86	elderly people 82	presentation 68
nypochromic anaemia 3	infants 3	prognosis 70–71, <b>71</b>
nypogammaglobulinaemia 91	laboratory investigations 2, 3–4	staging 69–71, <b>70</b>
nypoparathyroidism 7	management 4, 4, 4	supportive care 72
hyperviscosity 68	prevention 5	treatment 71–72
, , , , , , , , , , , , , , , , , , ,	iron loading 54	
brutinib 72, 96		M protein 59
leal resection 11	JAK2 gene 21, 96	macrocytic anaemias 7–12
matinib mesylate 30, 31	inhibitors 26, 96	macrocytosis 7
mmune stimulation, chronic 67	mutations 21, 22, 24	causes 7-10, <b>10</b>
mmune thrombocytopenia 44, 44, 47	jaundice	diagnosis 10–11
mmunoglobulin	G6PD deficiency 18	treatment 11–12
hyperviscosity 85	megaloblastic anaemia 8, 9	macrothrombocytopenia 43
intravenous 47		malabsorption, vitamin B <sub>12</sub> 7
multiple myeloma 55	koilonychia 2, 2	malaria 15, 18, 67
mmunoglobulin A (IgA) 55, 57	·	mantle cell lymphoma (MCL) 73
mmunoglobulin G (IgG) 44	lenalidomide 54, 59	May-Hegglin anomaly 43, 43
mmunomodulatory therapy 96	leucoerythroblastic blood film 25, 25, 26	mean cell volume (MCV) 82
lymphoproliferative disorders 71–72	leucostasis, acute leukaemias 35	macrocytosis 7, 10
mmunophenotyping 31, 35, 83	leukaemia	megaloblastic anaemia 8–9, 11
mmunosuppression	acute 33-39	causes 8
lymphoproliferative disorders 67	classification 34	elderly people 82
myelodysplastic syndromes 54	clinical features 34-35	melphalan 59
stem cell transplantation 76	diagnosis 35-37	menorrhagia 61, 63
nfants	differential diagnosis 34	mental retardation in α-thalassaemia 17
bleeding disorders 46	epidemiology 34	metamyelocytes 8
iron deficiency 3	genetic basis 33	methotrexate 38, 76, 77
platelet disorders 46	risk factors 33	methylmalonic acid 10, 82
sickle cell anaemia 15	supportive care 37, 37	micro RNAs 94
thalassaemias 17	treatment 37–39, <b>37</b>	microangiopathic thrombocytopenia 45
nfections 90–91, <b>90</b>	see also specific types	microarray technology 69, 94, 95
acute leukaemias 35	chronic see chronic lymphocytic leukaemia	monoclonal antibodies 96
allogeneic stem cell transplantation 77, 79	(CLL); chronic myeloid leukaemia (CML)	lymphoproliferative disorders 71
CLL 91, 91	hyperviscosity 85, 85	monoclonal gammopathy of undetermined
impaired immunity 90-91	myelofibrosis transformation 26	significance (MGUS) 55, 59
neutropenia 35, 91	polycythaemia transformation 23	diagnosis 57, <b>57</b>
nfertility 76	leukapheresis 86	older adults 83
folate deficiency 9	liver disease 63	mucosa-associated lymphoid tissue (MALT) 67,72
vitamin B <sub>12</sub> deficiency 9	lumbar puncture 37	multiple myeloma 55–59, 56
nflammation, chronic 67	lymph nodes 68	clinical features 55–57, <i>56</i> , 56, <i>57</i>
nsertional mutagenesis 93	biopsy 68	diagnosis 57, 57, 58







multiple myeloma (cont'd)	parvovirus infection 14	purpura 44
epidemiology 55	peripheral blood stem cell (PBSC)	post-transfusion 44
investigations 58	harvest 75	thrombotic thrombocytopenic (TTP) 45, 45,
management 59, 59	pernicious anaemia 7, 10	90, 90
stem cell transplantation 76	autoantibodies 10	pyruvate kinase deficiency 18
pathogenesis 55	pharyngeal webs 2	
prognosis 58	Philadelphia (Ph) chromosome 28, 28	radiotherapy
spinal cord compression 55, 57, 88	ALL 36	lymphoproliferative disorders 71
staging 58, <b>58</b>	CML 28, 28, 29	myelofibrosis 26
myelodysplasia 10, 11, 11	plasma cell leukaemia 59	rational drug design 96
macrocytosis 10	plasma cells, multiple myeloma 55, 56	receptor activator of nuclear kappa B
myelodysplastic syndromes 49–54	plasma exchange 90	(RANK-L) 55, 56
classification 50–51, <b>53</b>	plasmacytoma 57, 59, 87	recombinant coagulation factors 63
isolated 5q- associated syndromes 50	plasmapheresis 86	red cells
myelodysplastic/myeloproliferative	platelet count 89	aplasia 14, 19
neoplasms 51	raised 24	•
		enzyme defects 18
genetic mutations 49, 49, 50	investigation 24	folate assay 10
immune deregulation 49–50	reduction 25	membrane defects 18
investigations 50	platelet disorders 42–47, 89	sickling 14
management 52–54	acquired 43-45, 44	Reed-Sternberg cells 72, 73
future advances 54	congenital 42-43, 42, 43	renal failure, myeloma 57
older adults 83, 84	investigation 45-46, 46	rituximab 96
pathogenesis 49	management 46-47	acquired platelet disorders 47
presentation 50	storage pool diseases 43	chronic lymphocytic leukaemia 73
prognosis 51-52, <b>53</b>	platelet transfusions 47, 54, 89	lymphoproliferative disorders 67, 71
supportive care 52-54	disseminated intravascular coagulation	thrombotic thrombocytopenic purpura 90
therapy-related 50	89–90	rivaroxaban 65, 88
myelofibrosis 21	platelets 41	ruxolitinib 96
polycythaemia transformation 23	consumption increase 44	
poor prognostic features 26	decreased production 43, 44	sepsis 25, 35, 85
primary (PMF) 21, 25–26, 25	dense granules 41, 43	sickle cell anaemia 13–15, 86, 87
myeloma 55, 83, 83	function 41–42, 42	complications 15
clinical features 55–57	microvascular thrombi 45, 63, 90	diagnosis 14
stem cell transplantation 76	see also platelet count; platelet disorders;	infants 15
see also multiple myeloma		
	platelet transfusions	prevention 15
myeloproliferative disorders 21–26	Pneumocystis jirovecii 91	treatment 15
1 . 10.	polycythaemia vera (PV) 21, 22–23,	sickle cell crises 13–14, 15, 86–87
nails, iron deficiency anaemia 1-2, 2	22, 96	treatment 87
neonates	ponatinib 31	sickle cell gene 13
alloimmune thrombocytopenia 44	post-transfusion purpura 44	sickle cell trait 14
bleeding disorders 46	prednisolone 47, 90	sickling disorders 13-15, 86
macrocytosis 10	preeclampsia 45	variants 15
platelet disorders 46	pregnancy	Sjögren's syndrome 67
sickle cell anaemia prevention 15	folate deficiency 8, 9	skin, iron deficiency 1-2
neural tube defects 9	folic acid supplementation 9	small lymphocytic lymphoma 73
neuropathy, vitamin B <sub>12</sub> 7	iron deficiency anaemia 3	spina bifida 9
neutropenia 91	iron requirements 1	spinal cord compression 87-88
acute leukaemias 35	iron supplements 1	multiple myeloma 55, 57, 88
infections 91	macrocytosis 10	spleen, enlarged/splenomegaly
next generation sequencing (NGS) 94–95	microangiopathic thrombocytopenia 45	CML 27, 28
nilotinib 31	sickle cell anaemia 15	lymphoproliferative disorders 68
non-Hodgkin's lymphoma (NHL) 72	primary myelofibrosis (PMF) 21, 25–26, 25	thrombocytopenia 45
non-steroidal anti-inflammatory drugs	diagnostic criteria 25	splenectomy 18
(NSAIDs) 45, 89	prolymphocytic leukaemia (PLL) 68	acquired platelet disorders 47
non-vitamin-K antagonist oral	proteasome inhibitors 59	myelofibrosis 26
_	•	•
anticoagulants 65	protein C 64	thalassaemia 18
NPM mutation 36	protein S 64	spliceosome mutations 50
nuclear factor kappa β (NF-κΒ) 55, 96	prothrombin complex concentrates	stem cell transplantation 75–79, <b>76</b>
	(PCC) 88	ALL treatment 38
pesophageal webs 2	prothrombin gene mutation 64	allogeneic 76
oncolytic viruses 96	prothrombin time (PT) 62	complications 77-79, <b>77</b> , 78
oxymethalone 26	pulmonary embolism 63	AML treatment 38







thrombin inhibitors 88–89
thrombin time (TT) 62
thrombocytopenia 89–90
amegakaryocytic 42
heparin-induced 44-45, 47
immune 44, 44, 47
investigation 45-46
management 47
microangiopathic 45
MYH9-related 43, 43
neonatal alloimmune 44
with absent radii 42, 42
thrombocytosis 24–25, 45, 46
essential 45
reactive 45
thrombophilias, inherited 64–65, <b>64</b>
thrombotic thrombocytopenic
purpura (TTP) 45, 45,
90, 90
subtypes 90
ranexamic acid 47
transferrin receptors 3, 5, 82
tumour lysis syndrome 35
tyrosine kinase gene 21
tyrosine kinase inhibitors 30
CML treatment 30-31, 30
resistance to 31
second- and third-generation 31
treatment monitoring 30-31

ultra-large von Willebrand factor (ULVWF)
multimers 90
vascular endothelial growth factor (VEGF) 55
vegans 7, 12
venesection, polycythaemia 23
venous thromboembolism (VTE) 63, 64
treatment 65
viral vectors 93
vitamin B <sub>12</sub>
deficiency 7-8, 9, 82
malabsorption 7, 8
neuropathy 9
serum assay 10
treatment 11-12
vitamin K
bleeding management 88
deficiency 63
vitiligo 8
von Willebrand disease 43, 62, 63
von Willebrand factor (VWF) 41, 62, 63
bleeding disorders 62
Waldenström's macroglobulinaemia
57, 58
warfarin 47, 65, 88
Wiskott-Aldrich syndrome 42-43

 $zinc\ protoporphyrin\ assay\ 3$ 



